New stem cell transplant trial aims to treat sickle cell disease and other blood disorders
NCT ID NCT06872333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a stem cell transplant from a donor for people with high-risk sickle cell disease, thalassemia, and other red blood cell disorders. Participants receive drugs and low-dose radiation before the transplant to help the new cells take hold. The study will track how well the transplant works and watch for side effects like graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stem cell transplant (from a donor) with alemtuzumab, thymoglobulin, and total body irradiation
What this could lead to
If successful, this could offer a long-term treatment option for people with severe sickle cell disease and other blood disorders, potentially reducing or eliminating the need for blood transfusions.
What could go wrong
This is an early phase 2 trial with only 62 participants, so results may not apply to everyone. There are serious risks like graft-versus-host disease, graft failure, and side effects from the drugs and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOGLOBINOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact